Transcript - Biomed Town

Consensus Discussion
– Soft Tissue Strand
Co-ordinator Hans Gregersen
STEP Conference 15-16 May 2005
Introduction






Try to find common ground between organ
systems
Discuss strategy
Critical success factors
Define Common goals
Resources – head towards 7th frame work –
manpower, instrumentation, computers
Finances – How will it be funded ?
Barriers to Success









How do we get to the clinicians?
To know what data clinicians and industry need
Education of Bioengineers etc is also a problem.
Focus on specific areas – get approach right
Funding
Getting Collaborations off the ground.
IP Issues related to collaborations
Implications and understanding of free and open
source software.
Don’t know enough about healthy and diseased cases
What are Researchers Looking for ?









Need more data available between centres (share experimental
data)
Adaptation of Tissue – functional and biomechanical
remodelling
Multi-level Integration
Keep patho-physiological perspective
Common issues between tissues
Do not be driven too much by applications in the early stages
Need to predict the organ function
Not just focus on biomechanics
Develop a hypothesis which is focused on clinical application.
What are Clinicians looking for ?





Keep holistic approach and try to start therapies
in early stages
Need to supply complete specific examples of
how this could be of interest to Clinicians
Collaborations often come from desperation of
clinicians.
Clinician only wants output
Find our way into clinical practice
What are Industry Looking for ?








Medical Devices, Drugs and Software
Data Sharing
Teams involving industry
Models translated to the practice
Fully Validatible Predictive Models
The notion of time is extremely important to industry.
Need fast deliverable, structured outcome
Industry will buy what is successful.
Resources



We need EU to put aside money so that we can
show this is worthwhile for industry to fund.
There is money in Drug Companies and this is
more related to therapy rather than diagnosis.
Dilemma to work with small mobile cash poor
companies or large slow moving companies with
the money.
Other Issues






Patient Safety and Risk Management.
VPH might have Synergies with up to 3 platform
technologies.
Companies have their own Modelling Departments
Where are the Drug Companies ?
Make the clinician aware that there are tools to answer
there questions?
Make researchers aware that the clinicians have valuable
information?
How Do We Move Forward ?







Methods, Promotion and Domains (systems)
Need a structure to give us an effective steering.
Important to keep all the disciplines together .
However we do not want to be overwhelmed.
People from the same discipline will find each other.
The Multi-disciplinary grouping is better.
The structure is specific to the STEP, sub-groups on
any topic can spring up from biomed town
Marco’s Suggestion

Suggestion that we split into two groups
Infrastructure
 Clinical Uses


Including Pathology is a longer term Goal

Attendees:

Barry McMahon-Tallght Hospital
Liao Donghua-Aalborg Hospital
Odd H. Gilja-Haukeland University Hospital
Rod Smallwood - University of Sheffield
Joakim Sundnes - Simula Research Laboratory
Nikos Stergiopulos - Swiss Federal Institute of Technology
Frans C.T. van der Helm - TU Delf
Olivier Snoeck - Universite Libre de Bruxelles
Sabine Bensamoun - Universite de Technologie de Compiegne
Gerhard Holzapfel - Graz University of Technology
Peter Huijing - Vrije University
Hans Ulrich Kauczor - German Cancer Research Center
Chris Johnson - University of Utah
Peter Winlove - University Exeter
Jean-Pierre Boissel - Institute of Theoretical Medicine
Alfredo Hernandez - INSERM - Universite de Rennes
Veli Stroetmann - E-Health ERA
Marco Viceconti - Istituti Ortopedici Rizzoli
















